Bolt Biotherapeutics (BOLT) Competitors $4.84 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$4.83 -0.01 (-0.21%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock BOLT vs. SABS, CRIS, AMGN, GILD, VRTX, REGN, ALNY, BIIB, INCY, and UTHRShould you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include SAB Biotherapeutics (SABS), Curis (CRIS), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), and United Therapeutics (UTHR). These companies are all part of the "biotechnology" industry. Bolt Biotherapeutics vs. Its Competitors SAB Biotherapeutics Curis Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Incyte United Therapeutics Bolt Biotherapeutics (NASDAQ:BOLT) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends. Do institutionals and insiders believe in BOLT or SABS? 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 30.9% of Bolt Biotherapeutics shares are owned by insiders. Comparatively, 27.8% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable valuation & earnings, BOLT or SABS? SAB Biotherapeutics has lower revenue, but higher earnings than Bolt Biotherapeutics. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBolt Biotherapeutics$7.69M1.21-$63.12M-$26.66-0.18SAB Biotherapeutics$1.32M17.82-$34.10M-$4.00-0.57 Do analysts prefer BOLT or SABS? Bolt Biotherapeutics presently has a consensus price target of $47.50, indicating a potential upside of 881.40%. SAB Biotherapeutics has a consensus price target of $11.00, indicating a potential upside of 386.73%. Given Bolt Biotherapeutics' higher possible upside, equities analysts clearly believe Bolt Biotherapeutics is more favorable than SAB Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bolt Biotherapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BOLT or SABS more profitable? Bolt Biotherapeutics' return on equity of -91.67% beat SAB Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bolt BiotherapeuticsN/A -91.67% -53.19% SAB Biotherapeutics N/A -153.92%-89.16% Which has more risk & volatility, BOLT or SABS? Bolt Biotherapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Does the media prefer BOLT or SABS? In the previous week, SAB Biotherapeutics had 3 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 3 mentions for SAB Biotherapeutics and 0 mentions for Bolt Biotherapeutics. SAB Biotherapeutics' average media sentiment score of 0.53 beat Bolt Biotherapeutics' score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Bolt Biotherapeutics Neutral SAB Biotherapeutics Positive SummaryBolt Biotherapeutics beats SAB Biotherapeutics on 8 of the 15 factors compared between the two stocks. Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLT vs. The Competition Export to ExcelMetricBolt BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.29M$3.12B$5.76B$9.91BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-0.1821.0283.0126.65Price / Sales1.21379.56503.03163.66Price / CashN/A43.5325.7028.92Price / Book0.248.1210.796.52Net Income-$63.12M-$53.35M$3.29B$266.21M7 Day Performance-7.90%0.05%0.02%-0.76%1 Month Performance-13.88%7.08%7.06%3.83%1 Year Performance-63.34%11.92%50.09%24.39% Bolt Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLTBolt Biotherapeutics3.454 of 5 stars$4.84flat$47.50+881.4%-63.9%$9.29M$7.69M-0.1890SABSSAB Biotherapeutics2.95 of 5 stars$2.21+0.9%$11.00+397.7%-20.8%$22.85M$1.32M-0.55140News CoverageShort Interest ↓Gap DownCRISCuris2.5388 of 5 stars$1.65-3.2%$17.00+930.3%-67.3%$21.31M$10.91M-0.3460AMGNAmgen4.6592 of 5 stars$288.47-1.8%$304.43+5.5%-14.1%$158.13B$33.42B23.5928,000Trending NewsAnalyst ForecastGILDGilead Sciences4.9812 of 5 stars$114.15-0.5%$115.39+1.1%+41.8%$142.41B$28.75B22.7417,600Trending NewsVRTXVertex Pharmaceuticals4.9848 of 5 stars$388.94-1.6%$497.10+27.8%-16.6%$101.31B$11.02B27.806,100Positive NewsAnalyst ForecastREGNRegeneron Pharmaceuticals4.8122 of 5 stars$572.38-2.9%$829.65+44.9%-51.8%$62.48B$14.20B14.4215,106Positive NewsAnalyst UpgradeALNYAlnylam Pharmaceuticals3.9753 of 5 stars$443.64-2.4%$405.33-8.6%+76.3%$59.56B$2.25B-179.612,230News CoverageAnalyst ForecastBIIBBiogen4.9043 of 5 stars$136.36-2.1%$185.74+36.2%-30.9%$20.42B$9.68B13.047,605Trending NewsAnalyst ForecastINCYIncyte4.6599 of 5 stars$84.76-0.3%$81.60-3.7%+31.1%$16.61B$4.58B19.262,617News CoveragePositive NewsAnalyst ForecastShort Interest ↑UTHRUnited Therapeutics4.7251 of 5 stars$305.38-2.2%$382.00+25.1%+11.1%$14.08B$2.88B11.921,305Trending NewsAnalyst ForecastInsider TradeShort Interest ↑ Related Companies and Tools Related Companies SAB Biotherapeutics Alternatives Curis Alternatives Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives Incyte Alternatives United Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BOLT) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BOLT Stock Alerts